The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
28
No.
46
December 13, 2002
- As Amgen, Johnson & Johnson Battle Over Anemia Market, Medicare Enters The Fray
- Texas Oncology Designated Aranesp As Preferred Treatment
- After Congressional Inquiry, NCI Posts Ambiguous Statement On Abortion And Breast Cancer Risk
- Foundation Gives $1 Million To UPCI For Genetics Chair
- Funding Opportunities
CCL
Vol.
25
No.
12
December 27, 2002
- Dose Dense Chemotherapy Regimen Improves Survival In Breast Cancer
- Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer
- Arimidex Continues To Show Improvement Over Tamoxifen
- Iressa May Benefit Some Breast Cancer, Studies Find
- Gleevec Improves Survival Of CML In Accelerated Phase
- Phase II Study Tests Chemo Plus Mylotarg For AML
- “Proof Of Concept” Shown In Early Trial Of PKC-412
- Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis
- Clinical Trials Approved By NCI During November Are Listed
